logo

For the Inventor, By the Inventor

Handa, Japan

Riichiro Shibakawa

USPTO Granted Patents = 28

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 152(Granted Patents)


Location History:

  • Aichi, JA (1976 - 1977)
  • Handa, JA (1977 - 1978)
  • Handa, JP (1979 - 1986)

Company Filing History:

goldMedal28 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 1976-1986

Loading Chart...
28 patents (USPTO):Explore Patents
1. 4605624 - Nocardia species capable of producing nargenicin C.sub.1 (1986-08-12),
2. 4582796 - Erythromycin D and esters thereof by fermentation with Nocardia sp. ATCC (1986-04-15),
3. 4533553 - Polycyclic ether antibiotic (1985-08-06),
4. 4496546 - Erythromycin D and esters thereof (1985-01-29),
5. 4450237 - Streptomyces albus subspecies indicus (1984-05-22),
6. 4436747 - Nargenicin C.sub.1 (1984-03-13),
7. 4431801 - Polycyclic ether antibiotic (1984-02-14),
8. 4411892 - Tylosin macrolide antibiotics from streptomyces (1983-10-25),
9. 4361649 - Polycyclic ether antibiotic (1982-11-30),
10. 4287182 - Antibiotics produced by a new microbe, Catenuloplanes japonicus (1981-09-01),
11. 4247462 - Ansamycin antibiotic (1981-01-27),
12. 4225674 - Process for producing new ansamycin antibiotic (1980-09-30),
13. 4224314 - Antibiotics produced by species of Nocardia (1980-09-23),
14. 4212944 - Process for producing nocardicin A (1980-07-15),
15. 4195079 - New polycyclic ether antibiotic (1980-03-25),

Title: Innovations in Antibiotics: The Contributions of Riichiro Shibakawa

Introduction

Riichiro Shibakawa is a prominent inventor based in Handa, Japan, known for his significant contributions to the field of pharmacology and antibiotic research. With an impressive portfolio of 28 patents, Shibakawa has dedicated his career to developing innovative solutions to combat bacterial infections.

Latest Patents

Among his recent innovations, Shibakawa has been instrumental in the isolation and development of Nargenicin C.sub.1, a new antibiotic substance derived from the fermentation of a particular species within the genus Nocardia. This antibiotic has shown potential as an effective antibacterial agent against susceptible strains, notably Staphylococcus aureus. Additionally, he has contributed to the fermentation process of Nocardia sp. ATCC 39043, resulting in an antibiotic complex that includes erythromycin D and various esters. These components hold significant promise for both in vitro and in vivo applications against bacterial infections.

Career Highlights

Shibakawa's work primarily takes place at Pfizer Corporation, a leading global pharmaceutical company. His role has been pivotal in spearheading advancements that enhance antibiotic efficacy, reflecting his deep commitment to addressing critical health challenges through innovation.

Collaborations

Throughout his career, Shibakawa has collaborated with esteemed colleagues, including Walter D. Celmer and Walter P. Cullen. These partnerships have fostered an environment of creativity and innovation, ensuring the successful development of groundbreaking antibiotic therapies.

Conclusion

Riichiro Shibakawa's innovative approach and dedication to antibiotic research have positioned him as a key figure in the scientific community. His contributions not only enhance our understanding of bacterial resistance but also provide new avenues for effective treatment options. As he continues to tackle the challenges of infectious diseases, his work remains invaluable to the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…